论文部分内容阅读
目的：探讨右佐匹克隆联合黛力新治疗伴发失眠症状的焦虑抑郁状态患者的临床疗效。方法：将48例伴发失眠症状的焦虑抑郁状态患者随机分为两组，每组各24例，两组均给予黛力新抗焦虑抑郁，治疗组予以右佐匹克隆、对照组给予阿普唑仑改善睡眠情况，分别对两组患者治疗前及治疗8周后进行 HAM A 评分、HAMD评分，并对结果进行统计分析，同时通过分析患者治疗前后SDRS评分评价睡眠改善情况，并观察不良反应。结果：治疗8周后两组患者睡眠障碍均较治疗前有显著性改善（P＜0．01），组间比较虽无统计学意义，但治疗组不良反应事件的发生率显著低于对照组（P＜0．01）；治疗8周后两组患者 HAM A评分、HAMD评分均较治疗前明显下降（P＜0．01），组间比较，治疗组下降情况优于对照组（P＜0．05）。结论：右佐匹克隆联合黛力新治疗伴发失眠症状的焦虑抑郁状态患者疗效确切，不良反应少。“,”ObjectiveExplore joint eszopiclone Deanxit treatment of insomnia associated with anxiety and depression symptoms in patients with clinical efficacy .M ethodsThe 48 cases of insomnia symptoms of anxiety associated with depression were randomly divided into two groups ,24 cases in each group ,two groups were given Deanxit anxiety ,depression ,treatment group received eszopiclone ,control group was given alprazolam improve sleep quality ,respectively ,of two groups of patients before and after 8 weeks of treatment scores of HAM A , HAMD score ,and the results of statistical analysis ,both before and after treatment by analyzing sleep SDRS score evaluation to improve the situation and observe the adverse reactions .Results After 8 weeks ,patients were sleep disorders than those before treatment were significant-ly improved(P<0 .01) ,although no statistical significance between the two groups ,but the treatment group ,the incidence of adverse events was significantly lower than the control group(P<0 .01 );after 8 weeks ,patients were HAM A score ,HAMD score decreased significantly than before treatment(P<0 .01) ,between the two groups ,the treatment group than the control group decreased(P<0 .05) .Conclusion Es-zopiclone joint Deanxit treatment of insomnia associated with anxiety and depression symptoms in patients with efficacy ,adverse reactions .